Skip to main content
Transparency
Twitter
YouTube
Linkedin
cat
esp
eng
ABOUT US
RESEARCH
COVID-19
INNOVATION AND TRANSFER
LEARNING
LIVING LAB HEALTH
NEWS
COLLABORATE
Cerca
who are you?
Who are you?
I'm an
Investigator
I'm
Community
I'm an
Educator
or Student
I'm a
Collaborator
I'm a
Journalist
IrsiCaixa’s scientific activity search engine
Search by
Filter by strategic line
All lines
Immunopathogenesis
Microbiome
Other diseases
Prevention, eradication and functional cure
New treatments and resistance to antiretrovirals
Filter by research group
All the groups
Retrovirology and Clinical Studies (GREC)
Cell Virology and Immunology (VIC)
Microbial Genomics
Virus-Host Interactions (ViHIT)
Host Genetics and Cellular Immunity
HIV and HCV Genetic and Phenotypic Variability
Tissue Virology (VITI)
Viral Immune Evasion and Vaccines (VIRIEVAC)
Neoantigens and Therapeutic Vaccines for Cancer (NeoVaCan)
Pathogen immunity, signaling and therapeutic applications (PISTA)
Translational Research in Immunology and Aging (TRIA)
From Date
Date
To Date
Date
Search
Filter by category
Strategic lines
Research groups
Researchers
Projects
Publications
Clinical research
Events
Publication
2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies
Publication
Evaluation of the cytopathicity (fusion/hemifusion) of patient-derived HIV-1 envelope glycoproteins comparing two effector cell lines
Publication
Synthesis, biological activity, and ADME properties of novel S-DABOs/N-DABOs as HIV reverse transcriptase inhibitors
Publication
Synthesis, biological activity, and ADME properties of novel S-DABOs/N-DABOs as HIV reverse transcriptase inhibitors
Publication
Whole Genome Deep Sequencing of HIV-1 Reveals the Impact of Early Minor Variants Upon Immune Recognition During Acute Infection
Publication
In–Depth Characterization of Viral Isolates from Plasma and Cells Compared with Plasma Circulating Quasispecies in Early HIV-1 Infection
Publication
Low-Replicating Viruses and Strong Anti-Viral Immune Response Associated with Prolonged Disease Control in a Superinfected HIV-1 LTNP Elite Controller
Publication
Rare LEDGF/p75 genetic variants in white long-term nonprogressor HIV+ individuals
Publication
The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype
Publication
Viremic HIV Infected Individuals with High CD4 T Cells and Functional Envelope Proteins Show Anti-gp41 Antibodies with Unique Specificity and Function
« first
‹ previous
…
43
44
45
46
47
48
49
50
51
…
next ›
last »
IrsiCaixa: RT @FAQSTV3: -- El president del Parlament, Roger Torrent; els doctors Bonaventura Clotet i Oriol Mitjà, i el sociòleg portuguès Boaventura…
IrsiCaixa: -- Ha arribat el dia! El Dr Bonaventura Clotet, director d'IrsiCaixa, ha rebut avui la primera dosi de la vacuna. ---- #JoEmVacuno contra la COVID-19, per tothom qui no pot fer-ho i per poder tornar a abraçar-nos ben aviat! ---- Seguim
IrsiCaixa: ♀ Gracias a @NoMoreMatildas, una iniciativa de @twitamit_es, por visibilizar el #EfectoMatilda, dando a conocer logros de científicas eclipsados a lo largo de la historia e inspirando a futuras #MujeresEnCiencia. ------ Si quieres conoce
IrsiCaixa: RT @FeedbackToday: ¡Buenos días y feliz 2021! Ya estamos de vuelta con más entrevistas. Hoy os ofrecemos una entrevista con el Dr. Bonavent…
IrsiCaixa: --️ "S'ha d'insistir en què cal seguir estudiant, desenvolupant nous models i mantenint les mesures de precaució" Bonaventura Clotet, director d'IrsiCaixa, ara mateix a @elmonarac1 -- https://t.co/BmIN9M2lLI
IrsiCaixa: RT @elmonarac1: -- Tertúlia entre experts en la lluita contra el coronavirus --Bonaventura Clotet --@ToniTrilla --Magda Campins --@prieto_alham…
IrsiCaixa: RT @CCO_InfDis: Don't miss this #MedicalMinute presentation as Dr. Roger Paredes @RutgerWalls reviews safety and efficacy data on #COVIDー19…
IrsiCaixa: ------ Do not miss this webinar organised by the IrsiCaixa Living Lab for Health! Check it out here ---- https://t.co/LR1gT4j0Ub
IrsiCaixa: -- @diariARA | @jblanco_vic, d'IrsiCaixa, remarca la importància d'una vacunació global en el menor temps possible -- "Cal parlar de vacunes en plural. L'ideal és que hi hagi diferents empreses fabricant-ne i que cada va
IrsiCaixa: ------ L'Agència Europea de Medicaments aprova la #vacuna de #Moderna. L'investigador d'#IrsiCaixa @jblanco_vic remarca que la composició de les vacunes Pfizer-BioNTech i Moderna és molt similar i que "no ens hem de preo
Subscribe to our newsletter
I accept the sending of communications about IrsiCaixa activities, promotions and scientific and educational innovations
*
es
ca
en
Back to Top